The once-daily oral CSF-1R inhibitor was approved based on the phase 3 MANEUVER trial, which showed gains in tumor response, pain, and joint function.
Commentary|Videos|November 11, 2026
Oncology Pulsepoint: Ovarian Cancer Guideline Updates Expand Treatment Options and Pharmacists’ Role
Author(s)Jennifer MacDonald, PharmD, BCOP
In a Pulsepoint interview with Pharmacy Times, Jennifer MacDonald, PharmD, BCOP, discusses ovarian cancer guideline updates and pharmacists’ role in selecting therapies, managing toxicities, and preserving patients’ quality of life.
Advertisement
Advertisement
Ovarian cancer treatment updates are creating new opportunities for individualized care while adding complexity to medication management. In this PulsePoint interview, Jennifer MacDonald, PharmD, BCOP, a clinical pharmacy specialist in gynecologic oncology at MUSC Health, discusses how pharmacists can help translate evolving treatment recommendations into clinical practice.
Related to this article
On NET Cancer Day, a return visit for an over-the-counter antidiarrheal illustrates how pharmacists can identify a symptom pattern and help patients seek evaluation.
A community oncology pharmacist explains how seeing patients across the course of their diagnosis builds trust and why accessibility remains the field’s biggest challenge despite advances in AI.
Adding the IL-15 agonist to frontline BCG improved responses in carcinoma in situ without new safety signals; full data are expected at an upcoming congress.
At SITC 2026, 10 of 15 patients with advanced melanoma responded to investigational amsokigene autoleucel at the recommended phase 2 dose, with 5 still in response 12 months after infusion.
Specialty pharmacists can help patients with cancer weigh the benefits and risks of GLP-1 receptor agonists as use expands and new evidence emerges.
Matthew Porteus, MD, PhD, highlighted preclinical advances in automated stem cell gene editing that could improve manufacturing scalability while supporting the development of next-generation genetic medicines.
Payer requirements, prescriber habits, and operational realities ultimately determine which ICI patients receive.
Advertisement
Advertisement